Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBPP) Income from Continuing Operations (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Income from Continuing Operations for 13 consecutive years, with 572471.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 111.44% to 572471.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 1274502.0, a 90.72% decrease, with the full-year FY2025 number at 1274502.0, down 90.72% from a year prior.
  • Income from Continuing Operations was 572471.0 for Q3 2025 at Regen BioPharma, down from 167292.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 13047.0 in Q1 2021 to a low of 572471.0 in Q3 2025.
  • A 5-year average of 182475.84 and a median of 128529.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: soared 93.72% in 2021, then crashed 812.52% in 2022.
  • Regen BioPharma's Income from Continuing Operations stood at 141432.0 in 2021, then plummeted by 240.25% to 481226.0 in 2022, then surged by 69.88% to 144932.0 in 2023, then crashed by 255.6% to 515384.0 in 2024, then fell by 11.08% to 572471.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Income from Continuing Operations are 572471.0 (Q3 2025), 167292.0 (Q2 2025), and 19355.0 (Q1 2025).